Virginia Commonwealth University

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

Daniele Simoni

Walter Cabri

Claudio Pisano

Paolo Carminati

Giuseppe Giannini

Ruey-min Lee

Riccardo Baruchello

The present invention relates to formula I compounds having antitumoural activities through, as one possible biological target, the molecular chaperone heat shock protein 90 (Hsp90) inhibition. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of Hsp90 is responsive, and the pharmaceutical compositions containing such compounds. 

Aryl isoxazole compounds with antitumoural activities

Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes may also disrupt abnormal vessels in tumor to achieve vascular disrupting effect to suppress tumor growth. Water soluble pro-drug forms of stilbene derivatives are particularly useful in suppressing tumor growth in vivo.

Stilbene derivatives as new cancer therapeutic agents

Growing community of inventors

Ferrara, Italy

Daniele Simoni